default author photo

Alfredo Falcone

University of Pisa - Department of Oncology

Pisa

Italy

SCHOLARLY PAPERS

4

DOWNLOADS

381

TOTAL CITATIONS

15

Scholarly Papers (4)

1.

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

Number of pages: 126 Posted: 16 Nov 2019
University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, ARNAS Garibaldi Catania, Fondazione IRCCS Casa Sollievo della Sofferenza, Ospedale degli Infermi, University Campus Biomedico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), University of Pisa - Department of Oncology, F. Spaziani Hospital, Università degli Studi di Udine, Fondazione Poliambulanza, Istituto Oncologico Veneto – IRCCS, S. Croce and Carle Teaching Hospital, Government of the Italian Republic (Italy) - National Cancer Institute, University of Pisa - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, ARNAS Garibaldi Catania, Careggi University Hospital of Florence, University of Messina, University of Pisa - Department of Oncology, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, General Hospital, Prato, University of Naples Federico II, Ente Ospedaliero Ospedali Galliera, AOU Città della Salute e della Scienza di Torino, Massa Carrara, University of Rome Tor Vergata, Azienda Toscana Nord Ovest, IRCCS Ospedale San Martino IST, Candiolo Cancer Institute, Ospedale Santa Maria della Misericordia, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, University of Pisa, University of Pisa, Careggi University Hospital of Florence, University of Pisa - Department of Oncology and affiliation not provided to SSRN
Downloads 189 (409,459)
Citation 14

Abstract:

Loading...

2.

Atypical RAS Mutations in Metastatic Colorectal Cancer

Number of pages: 31 Posted: 13 Apr 2019
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Foundation Medicine, Inc., Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Foundation Medicine Inc., National Cancer Center Hospital East, Foundation Medicine Inc., Sungkyunkwan University - Department of Medicine, Catholic University of Milan - Fondazione Policlinico Universitario Agostino Gemelli, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Foundation Medicine, Inc., Foundation Medicine Inc., Sungkyunkwan University - Division of Hematology-Oncology, National Cancer Center Hospital East, University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department, University of Pisa - Department of Oncology, Memorial Sloan Kettering Cancer Center - Department of Pathology and University of Pisa - Department of Oncology
Downloads 100 (689,572)

Abstract:

Loading...

colorectal cancer; RAS mutations; atypical; anti-EGFR treatment; tumor mutational burden

3.

First-Line Panitumumab Plus FOLFOX-4 Followed by Maintenance Therapy with Single-Agent Panitumumab or Panitumumab Plus 5-FU/LV in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Valentino Study

Number of pages: 107 Posted: 05 Oct 2018
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa - Department of Oncology, Humanitas University - Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Grande Ospedale Metropolitano Niguarda, University of Turin, Azienda Ospedaliero-Universitaria Careggi, Ente Ospedaliero Ospedali Galliera, University of Messina, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Humanitas University, Università degli Studi di Genova, Fondazione Poliambulanza, University of Messina, University of Messina, Azienda Socio Sanitaria Territoriale Lariana, Azienda Socio Sanitaria Territoriale Bergamo Ovest, Azienda Ospedaliera San Gerardo, Ospedale Antonio Perrino, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department
Downloads 54 (1,041,696)

Abstract:

Loading...

colorectal cancer; maintenance treatment; panitumumab; RAS wild-type; randomised trial

4.

Genetic Variants Involved in the cGAS-STING Pathway Predict Outcome in Patients with Metastatic Colorectal Cancer: Data from FIRE-3 and TRIBE Trials

Number of pages: 16 Posted: 06 Apr 2022
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Charité–Universitätsmedizin Berlin, University of Southern California, University of Southern California - Norris Comprehensive Cancer Center, University of Southern California - Norris Comprehensive Cancer Center, University of Southern California - Norris Comprehensive Cancer Center, University of Southern California - Norris Comprehensive Cancer Center, University of Southern California - Norris Comprehensive Cancer Center, University of Southern California - Norris Comprehensive Cancer Center, affiliation not provided to SSRN, University Hospital of Pisa - Unit of Medical Oncology, affiliation not provided to SSRN, LMU Munich - Department of Hematology/Oncology, University of Pisa - Department of Oncology, Peking University - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), University of Southern California and University of Southern California - Norris Comprehensive Cancer Center
Downloads 38 (1,209,354)
Citation 1

Abstract:

Loading...

STING, Colorectal cancer, Cetuximab, biomarker